Pfizer Pledges up to US$4.4 B for Myovant’s Orgovyx

By Sasha Yachu & Michelle Liu

Pharma Deals Review: Vol 2021 Issue 4 (Table of Contents)

Published: 15 Apr-2021

DOI: 10.3833/pdr.v2021.i4.2606     ISSN: 1756-7874

Section: Licensing



Highlighting its commitment towards oncology and women’s health, Myovant Sciences has announced a collaboration with Pfizer to develop and commercialise OrgovyxTM (relugolix) in advanced prostate cancer in the US and Canada...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details